Early detection remains a key objective in the development of hepatitis C virus (HCV) diagnostic assays. Determining how early antibodies can be detected following infection requires high-quality, well-characterized seroconversion panels that accurately reflect the course of the immune response.
Recent independent clinical evaluations of novel anti-HCV immunoassays have included BIOMEX HCV seroconversion panels to assess assay sensitivity during the early stages of infection. These studies demonstrate the important role of reliable reference materials in evaluating diagnostic performance and comparing new assays with established methods.
Among the reported findings were:
- Excellent clinical sensitivity and specificity
- Reliable detection across all major HCV genotypes
- Early seroconversion performance comparable to established reference assays
In one Beckman Coulter evaluation of 30 commercial seroconversion panels, including three BIOMEX panels, the investigated assay detected seroconversion with an average difference of less than one day compared with the reference method.
Seroconversion panels play a vital role throughout assay development and validation. By providing well-characterized longitudinal samples, they enable developers to assess analytical performance, determine early detection capabilities and generate reliable clinical evidence for new diagnostic tests.
BIOMEX has been supplying high-quality seroconversion panels for more than 30 years, supporting diagnostic manufacturers worldwide with reference materials for assay development, validation and performance evaluation.
Related Publications
Explore the publications featuring BIOMEX HCV seroconversion panels:
